Transfusion of erythrocytes (RBC) to treat acute or chronic anemia has significant
drawbacks, given the risks of transfusion, volunteer donor requirements, limited supply with …

For as long blood transfusion has been in medical practice, creating an infusible product that
minimizes the complications associated with human blood products has been a laudable …

Oxygen delivery has evolved as a therapy of widespread interest in the clinical setting,
especially in emergency medicine and anesthesiology. With the widespread recognition of …

Hemoglobin-based oxygen carriers (HBOCs) have a storied history. The 1980s and 1990s
were a period of significant investment and development in the oxygen therapeutic market …

Considerable progress has been made in the development of the hemoglobin based
oxygen carriers (HBOCs), with a number of products in the final stages of clinical …

Blood transfusion is the key life-saving treatment in many traumatic emergencies, chronic or
acute pathologies, and during or upon surgical interventions. The primary goal of blood …

Currently, hemoglobin (Hb)-based oxygen carriers (HBOCs) are leading candidates as red
blood cell substitutes. In addition, HBOCs are also potential oxygen therapeutics for …

Immense scientific and commercial efforts continue to be undertaken to develop a safe and
effective synthetic oxygen-carrying solution that can be used in place of blood or packed red …

Haemoglobin-based oxygen carriers are being developed for use in blood replacement
therapies, either for perioperative haemodilution or for resuscitation from haemorrhagic …

SEMISYNTHETIC or synthetic preparations of hemoglobin, now termed hemoglobin-based
oxygen carriers (HBOCs), have been in development as an alternative to erythrocytes for …